SCHEMBL4244243

SCHEMBL4244243

COc1ccc(C(C(N)=O)C(=O)Nc2ncc[nH]2)cc1

nearest known ligand 0.50

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ FFAR2 O15552 1/20 0.50
▸ HPGDS O60760 1/20 0.47
▸ FPR2 P25090 1/20 0.44
▸ ADRA2A P08913 1/20 0.43
▸ ADRA2C P18825 1/20 0.43
▸ ADRA1D P25100 1/20 0.43
▸ ADRA1A P35348 1/20 0.43
▸ ADRA1B P35368 1/20 0.43
▸ ALPL P05186 1/20 0.42
▸ BRAF P15056 1/20 0.41
▸ HDAC1 Q13547 1/20 0.41
▸ AURKA O14965 2/20 0.39
▸ RPS6KB1 P23443 2/20 0.39
▸ ALDH1A1 P00352 1/20 0.39
▸ GAA P10253 1/20 0.39
▸ HTT P42858 1/20 0.39
▸ SMN1; SMN2 Q16637 1/20 0.39
▸ MEN1 O00255 1/20 0.38
▸ RAB9A P51151 1/20 0.38
▸ KMT2A Q03164 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4242107 0.86 FFAR2 (0.53) FFAR2HPGDSALPLAURKARPS6KB1
SCHEMBL4239786 0.83 FFAR2 (0.67) FFAR2FPR2ADRA2AADRA2CADRA1D
SCHEMBL4242694 0.83 FFAR2 (0.50) FFAR2HDAC1ALDH1A1ROCK2NR3C2
SCHEMBL4247079 0.83 FFAR2 (0.49) FFAR2ADRA2AADRA2CADRA1DADRA1A
SCHEMBL11781274 0.76 HPGDS (0.66) HPGDSBRAFHDAC1ALDH1A1GAA
SCHEMBL4240372 0.75 FFAR2 (0.44) FFAR2HPGDSFPR2RPS6KB1NR3C2
SCHEMBL4243620 0.74 FFAR2 (0.43) FFAR2HPGDSFPR2ADRA2AADRA2C
SCHEMBL4240812 0.74 FFAR2 (0.44) FFAR2AURKARPS6KB1ROCK2NR3C2
SCHEMBL4239132 0.74 FFAR2 (0.52) FFAR2ADRA2AADRA2CADRA1DADRA1A
SCHEMBL4593652 0.72 CA1 (0.57) MEN1RAB9AKMT2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20060223849-A1 Benzazole derivatives, compositions, and methods of use as beta-secretase inhibitors HIGH POINT PHARMACEUTICALS, LLC 2006-10-05 — — US claimed
US-8946259-B2 Benzazole derivatives, compositions, and methods of use as beta-secretase inhibitors HIGH POINT PHARMACEUTICALS, LLC (US) 2015-02-03 — — US disclosed
US-20140066477-A1 Benzazole Derivatives, Compositions, and Methods of Use as Beta-Secretase Inhibitors HIGH POINT PHARMACEUTICALS, LLC (US) 2014-03-06 — — US disclosed
US-8598353-B2 Benzazole derivatives, compositions, and methods of use as β-secretase inhibitors HIGH POINT PHARMACEUTICALS, LLC (US) 2013-12-03 — — US disclosed
EP-2457901-A1 Benzazole derivatives, compositions, and methods of use as B-secretase inhibitors High Point Pharmaceuticals, LLC (US) 2012-05-30 — — EP disclosed
US-20090326006-A1 Benzazole Derivatives, Compositions, and Methods of Use as Beta-Secretase Inhibitors VTVX HOLDINGS II LLC 2009-12-31 — — US disclosed
US-20060223849-A1 Benzazole derivatives, compositions, and methods of use as beta-secretase inhibitors HIGH POINT PHARMACEUTICALS, LLC 2006-10-05 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090326006-A1 Benzazole Derivatives, Compositions, and Methods of Use as Beta-Secretase Inhibitors BACE1, BACE2, APP FFAR2 4632/4885HPGDS 2231/4885FPR2 3721/4885
US-20060223849-A1 Benzazole derivatives, compositions, and methods of use as beta-secretase inhibitors BACE1, BACE2, APP FFAR2 4632/4885HPGDS 2231/4885FPR2 3721/4885
US-20140066477-A1 Benzazole Derivatives, Compositions, and Methods of Use as Beta-Secretase Inhibitors BACE1, BACE2, APP FFAR2 4632/4885HPGDS 2231/4885FPR2 3721/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback